

# 8 Chloro-Adenosine in Chronic Lymphocytic Leukemia (CLL)

A Phase I Study of 8-Chloro-Adenosine in Previously Treated Patients with Chronic Lymphocytic Leukemia

## Objectives:

- To determine the highest safe dose of the drug 8-chloro-adenosine that can be given in the treatment of CLL
- To learn how effective the 8 Chloro-Adenosine is at treating leukemia

## Eligibility Criteria:

- Diagnosis of CLL and must be previously treated with at least one regimen, including a purine-analogue based treatment
- Zubrod performance status of 2 or less
- Age 18 or greater
- No treatment for 4 wks prior to enrollment
- Adequate renal and liver function
- Pre-treatment platelets of at least 50,000/ul and not requiring transfusion unless thrombocytopenia due to marrow disease
- No active uncontrolled infection
- No uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia purpura
- No pregnant or breast-feeding females

## Benefits for Patients:

- Treatment on this study may help to control CLL
- Future patients may benefit from what is learned



## Procedures:

- A dose escalation study
- All patients will be enrolled and treated at MD Anderson
- Patients will be treated in groups of 3. The dose of drug will be increased with each new group until the highest safe dose is found
- 8 Chloro-adenosine will be given as an infusion into a vein once a day for one hour for 5 days in a row
- This 5-day treatment will be repeated every 4 weeks for 6 courses
- Routine blood tests are done at screening to determine eligibility
- Blood tests will be done on Day 3 and 5 of course 1 of treatment then weekly
- A physical exam will be done and side effects will be assessed at each weekly visit
- If the disease improves, the doctor will request that a bone marrow biopsy be done to confirm complete remission
- Treatment will continue if the disease is stable
- Monitoring may be done by referring physician.

## Protocol # 2004-0144

**Principal Investigator: William Wierda, MD, PhD**

Schedule an appointment or make referral online at [https:// my.mdanderson.org](https://my.mdanderson.org) or call (713) 563-2000.

For more information about the study, contact Dr. Wierda at (713)745-0428 or [wwierda@mdanderson.org](mailto:wwierda@mdanderson.org)

For information on related articles or references for this study, visit <http://physicianrelations.org>

or <http://www.clinicaltrials.gov/ct2/show/NCT00714103>

THE UNIVERSITY OF TEXAS

**MD Anderson  
Cancer Center**

Making Cancer History®